Project Management Simplified

Imexpharm’s EBITDA margin rises to 22.3 per cent driven by cost management and growth

In September 2025, Imexpharm’s profit before tax surged by 101 per cent, while EBITDA increased by 48 per cent.

一些您可能无法访问的结果已被隐去。